Ethnic and clinical differences in gBRCA and HRD mutated breast and ovarian cancers and their response to PARP inhibitors.

被引：0

作者：

Uttamchandani, Ashok

Syed, Naveed

Chintakuntlawar, Ashish Vittalrao

Afrooz, Imrana

Chandani, Kanishka Uttam

Al Hasan, Riad

Vilasini, Deepthi

Al Salami, Aisha Mohamed

Chehal, Aref Ahmad

机构：

[1] Sheikh Shakbout Med City, Abu Dhabi, U Arab Emirates

[2] Sheikh Shakhbout Med City Partnership Mayo Clin, Abu Dhabi, U Arab Emirates

[3] Landmark Med Ctr, Woonsocket, RI USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e13102

引用

页数：1

共 40 条

[1] PARP inhibition in BRCA-mutated breast and ovarian cancers
Chan, Stephen L.
Mok, Tony
LANCET, 2010, 376 (9737): : 211 - 213
[2] The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
Drew, Yvette
Calvert, Hilary
RECENT ADVANCES IN CLINICAL ONCOLOGY, 2008, 1138 : 136 - 145
[3] CLINICAL ONCOLOGY PARP inhibitors for all ovarian cancers
Carmona, Javier
NATURE MEDICINE, 2019, 25 (11) : 1647 - 1647
[4] Predictive value of HRD testing on the response to PARP inhibitors in ovarian cancer preclinical models
Dellavedova, Giulia
Decio, Alessandra
Formenti, Laura
Porcu, Luca
Ghilardi, Carmen
Giavazzi, Raffaella
Bani, Maria Rosa
CANCER RESEARCH, 2023, 83 (07)
[5] PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
Mehta, Prashant
Bothra, Sneha J.
ADVANCES IN GENETICS, VOL 108, 2021, 108 : 35 - 80
[6] THE ROLE OF PARP INHIBITORS IN THE MAINTENANCE OF RESPONSE IN PLATINUM SENSITIVE RECURRENT OVARIAN CANCERS
Khoury, Emma G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A240 - A240
[7] PARP Inhibition in advanced gBRCA1/2 mutated Breast Cancer New AGO Guideline on Breast cancer published: PARP Inhibitors have highest possible Level of Recommendation
不详
BREAST CARE, 2021, 16 (03)
[8] PARP Inhibition in advanced gBRCA1/2 mutated Breast Cancer New AGO Guideline on Breast Cancer published: PARP Inhibitors have the highest possible Level of Recommendation
不详
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 366 - 366
[9] Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer
Nozaki, Takahiro
Sakamoto, Ikuko
Kagami, Keiko
Amemiya, Kenji
Hirotsu, Yosuke
Mochizuki, Hitoshi
Omata, Masao
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (04)
[10] PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
Kamel, Dalia
Gray, Christopher
Walia, Jagdeep Singh
Kumar, Vikaash
CURRENT DRUG TARGETS, 2018, 19 (01) : 21 - 37

← 1 2 3 4 →